TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

robot
Abstract generation in progress

Tempest Therapeutics’ stock (TPST) crashed following its announcement to acquire two preclinical CAR-T programs from a privately held biotechnology company in an all-stock transaction. The deal, which includes a leading program for relapsed/refractory multiple myeloma, could be worth up to $225 million in milestone payments. This news overshadowed the positive clinical update on TPST-1120 for cholangiocarcinoma.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin